SPRIM Global Investments

Overview

SPRIM Global Investments is a privately held investment firm specializing in clinical-stage life sciences and pharma services. Established in 2008, the firm provides equity investment, debt, and royalty financing to clinical-stage biotech companies and late-stage medtech firms. SPRIM Global Investments operates globally, with offices in Singapore and New York City, and offers its portfolio companies access to a network of experts across 17 offices worldwide. The firm's investment strategy focuses on companies that provide R&D capabilities to bring life science innovations to patients globally. SPRIM Global Investments invests in biotech, medtech, and digital health companies, addressing various challenges across different clinical stages of drug and device development. The firm offers flexible funding models, including direct equity investments, venture debt financing through specialized vehicles, and venture funds. In March 2025, SPRIM Global Investments announced a $300 million joint venture with One Investment Management to accelerate clinical trial financing. This partnership aims to expand SPRIM's specialized financing platform, TrialCap, which supports clinical trials from Phase 1 through Phase 3. The collaboration seeks to provide critical financing solutions that drive innovation in life sciences, helping biotech and medtech companies advance groundbreaking therapies and accelerate time-to-market.